SanDisk Corporation (NASDAQ:SNDK) fell 1.33% in pre-market trading down to $54.98 after analyst Mark Delaney of Goldman Sachs downgraded the company to Neutral and cut his price target from $73 to $55. According to The Fly, Delaney downgraded the semiconductor company due to increasing supply and decreasing smartphone demand. The analyst estimates that there will be a 3% oversupply of NAND chips in 2015. After several mergers and acquisitions in the semiconductor arena, Delaney believes this consolidation is now less likely as the technology sector is beginning to direct capital away from NAND production. According to the 20 analysts polled by TipRanks in the last 3 months, 10 are bullish on the stock, 8 remain on the sidelines, and 2 are bearish. The average 12-month price target between these 20 analysts is $63.61, marking a 14% potential upside from where shares last closed.
Altria Group Inc (NYSE:MO) shares jumped 5.69% in pre-market trading to $57.19 after rumors came out that beer company Anheuser-Busch Inbev DA could take over rival SABMiller. Anheuser-Busch confirmed it will make an offer to buy SABMiller. The combined company would dominate the beer industry, controlling half the profit in the arena. Altria is the biggest shareholder in SABMiller, which owns Miller Beers, Blue Moon, Strongbow, and others. Altria’s website highlights their 27% ownership in SABMiller and $1 billion earnings from the ownership in 2014. According to TipRanks, one analyst has weighed in on Altria in the last 3 months with a bullish rating and a $62 price target, marking a 14% potential upside from current levels.
Geron Corporation (NASDAQ:GERN) spiked 3.94% in pre-market trading to $3.69 after the biopharmaceutical company announced the beginning of its Phase 2 trial for imetelstat in patients with myelofibrosis, or MF. Imetelstat is a pipeline drug delivered in IV form aimed to treat hematologic malignancies. The trial is being conducted alongside Janssen Biotech due to the collaboration between the two companies agreed upon in November 2014. The Phase 2 trial will enroll about 200 patients in order to test the safety and efficacy of two doses. All 3 of the analysts polled by TipRanks in the last 3 months are bullish on Geron. The 3 analysts have a 12-month average price target of $5.50, marking a 55% potential upside from current levels.